The results of a clinical trial of a personalized mRNA-based vaccine for patients with pancreatic cancer have been published in the United States. The study, conducted at Memorial Sloan Kettering Cancer Center under the direction of oncologist Vinod Balachandran, showed that nearly half of the participants were alive six years after treatment, significantly exceeding standard survival rates for this diagnosis.
In the first phase of the trial, 16 patients who had undergone surgical tumor removal were enrolled. After surgery, they all received a comprehensive treatment: an individually developed mRNA vaccine, chemotherapy, and an immunotherapy drug. As a result, in eight of the sixteen patients, the immune system produced a pronounced response — T cells capable of recognizing and attacking cancer cells were detected. Of this group, seven people remained alive four to six years after starting treatment. By comparison, the average five-year survival rate for pancreatic cancer usually does not exceed 13%.
Immunity for years
Scientists note that the vaccine not only activates the immune system immediately after administration, but also promotes the formation of long-lived T-cells. These cells are capable of controlling potential tumor recurrence for years. Even after successful surgery, the risk of recurrence in pancreatic cancer remains high, and standard treatment methods are often insufficiently effective. Therefore, the development of new approaches, including therapeutic vaccines, is becoming a priority in oncology.
Technology and a personalized approach
The vaccine is developed individually for each patient based on genetic analysis of the tumor. This approach makes it possible to identify unique mutations and train the immune system to recognize them. Although the study involved a small number of patients and is still preliminary, an international phase two trial with a broader cohort has already begun. The authors emphasize that the key objective is to achieve a strong immune response in more patients, not only to destroy the primary tumor but also to prevent its return in the future.
Context and outlook
mRNA technologies, which became widely used during the COVID-19 pandemic, are now actively being introduced in oncology as well. Personalized vaccines are seen as a promising direction for precision medicine. However, despite encouraging results, researchers note that several issues remain to be addressed—in particular, increasing the effectiveness of the immune response in a larger number of patients.
Questions of long-term survival and new treatment methods for cancer are regularly discussed in international medical circles. As with other sensitive topics related to health and safety, interest in new approaches remains high. For example, earlier in Catalonia, there was discussion about a troubling situation following a teenager’s attack on a peer, which sparked a wave of concern among local residents— details of the incident were provided in our report.
